Page last updated: 2024-08-22

stanozolol and Osteoporosis, Postmenopausal

stanozolol has been researched along with Osteoporosis, Postmenopausal in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hampl, R; Kancheva, RL; Zofková, I	1
Kancheva, RL; Röjdmark, S; Zofková, I	1

Trials

1 trial(s) available for stanozolol and Osteoporosis, Postmenopausal

Article	Year
A decreasing CD4+/CD8+ ratio after one month of treatment with stanazolol in postmenopausal women. Steroids, 1995, Volume: 60, Issue:7 Topics: Anabolic Agents; CD4-CD8 Ratio; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Sex Hormone-Binding Globulin; Stanozolol	1995

Other Studies

1 other study(ies) available for stanozolol and Osteoporosis, Postmenopausal

Article	Year
Stanazolol--an anabolic steroid that does not influence parathyroid hormone response to hypercalcemia in postmenopausal women. Calcified tissue international, 1994, Volume: 54, Issue:6 Topics: Administration, Oral; Anabolic Agents; Calcium; Dose-Response Relationship, Drug; Estrogens; Female; Humans; Hypercalcemia; Luteinizing Hormone; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Postmenopause; Radioimmunoassay; Stanozolol; Testosterone; Time Factors	1994

Article

Year

Stanazolol--an anabolic steroid that does not influence parathyroid hormone response to hypercalcemia in postmenopausal women.

Calcified tissue international, 1994, Volume: 54, Issue:6

Topics: Administration, Oral; Anabolic Agents; Calcium; Dose-Response Relationship, Drug; Estrogens; Female; Humans; Hypercalcemia; Luteinizing Hormone; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Postmenopause; Radioimmunoassay; Stanozolol; Testosterone; Time Factors

1994